ERBB2 and breast cancer: A pooled analysis of 3771 patients with BC demonstrated that quantifying TILs before NAT predicts therapeutic efficacy and is related to patient survival, with the exception of patients with luminal HER2-BC8; however, the simple single status ‘before NAT’ does not precisely describe patient immune characteristics.